136656-07-0
136656-07-0 结构式
基本信息
知母皂苷BII
知母皂苷BII(标准品)
知母皂苷BⅡ(分析标准品)
知母皂苷 BII, 来源于知母
知母皂苷BII、原知母皂苷A3
知母皂苷BII 136656-07-0
TIMOSAPONIN BII 知母皂苷BII
TIMOSAPONIN BII 知母皂苷BII 标准品
Timosaponin B2
Timosaponin BII
Prototimosaponin A III
Timosaponin BII USP/EP/BP
Anemarsaponin BII, 98%, from Anemarrhena asphodeloides Bunge
(25S)-26-(β-D-Glucopyranosyloxy)-3β-[(2-O-β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-5β-furostan-22-ol
(25S)-3β-[(2-O-β-D-Glucopyranosyl-β-D-galactopyranosyl)oxy]-26-(β-D-glucopyranosyloxy)-5β-furostane-22-ol
β-D-Galactopyranoside, (3β,5β,22α,25S)-26-(β-D-glucopyranosyloxy)-22-hydroxyfurostan-3-yl 2-O-β-D-glucopyranosyl-
物理化学性质
常见问题列表
Timosaponin BII is a steroidal glycoside separated from Zhi Mu, is found to have the inhibitory activity against the proliferation of HL-60 (leukemic), Hela (cervix), HepG2 and Bel-7402 (liver), HT-29 (colon), and MDA-MB-468 (breast) human carcinoma cell lines with an IC 50 value of 15.5 μg/mL in the HL-60 cells.
Rat retinas in model group and vehicle control group manifest an apparent up-regulation of BACE1 expression. Meanwhile, the level of malonaldehyde (MDA), Aβ1-40 and β-CTF are increased. However, when comparing with the vehicle control group, the retinas in Timosaponin-BII treated group showed significantly less BACE1 and accumulated less Aβ1-40 or β-CTF. It also showed significantly decreased level of MDA and prolonged partial thromboplastin time.